8-K - Citius Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Citius Oncology announced a commercial update for LYMPHIR™, highlighting strong early adoption with 83% of target accounts progressing through formulary and ~80% of covered lives secured.

Key Takeaways

183% of target accounts have added or are actively progressing LYMPHIR through formulary review, indicating strong institutional uptake.

2Broad market access established with ~135 health plans representing ~80% of covered lives secured and no reported reimbursement denials.

3Sequential growth in orders observed with initial accounts placing repeat orders, supporting early prescribing continuity.

4Initial penetration into community infusion centers is underway as patients transition from larger cancer centers.

5Positive topline data presented from a University of Minnesota study evaluating LYMPHIR prior to CAR-T therapy.

6Management estimates the initial market for LYMPHIR currently exceeds $400 million and is growing.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events.** On March 31, 2026, Citius Oncology, Inc. (Nasdaq: CTOR), our majority-owned subsidiary, issued a press release announcing a commercial update on

Other Event

9.01

. Financial Statements and Exhibits.** (d) Exhibits | Exhibit No . | | Description | |---|---|---| | 99.1 | | Press release, dated March 31, 2026. | | 104 | | C

Exhibits Only

Source Document

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE, DATED MARCH 31, 2026